Project Oncology®

What are the current rationales for the use of adjuvant therapies in the management of early-stage breast cancer patients? Here to share some insights is Dr. Lajos Pusztai, Director of Breast Cancer Translational Research at the Yale Cancer Center.

Mesothelioma is a cancer with limited treatment options, so how can we manage it in the first and second-line settings and beyond? Here with Dr. Jacob Sands to walk us through the various treatment approaches to mesothelioma is Dr. Aaron Mansfield, Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.

The NCCN Clinical Practice Guidelines in Oncology provide a wealth of information in the therapeutic management of early breast cancer. But how do those guidelines vary based on tumor biology? Here to give us a brief overview is Dr. Rachel Jimenez, Associate Program Director at the Harvard Radiation Oncology Residency Program in Boston.

The NCCN Clinical Practice Guidelines in Oncology provide a wealth of information in the therapeutic management of early breast cancer. But how do those guidelines vary based on tumor biology? Here to give us a brief overview is Dr. Rachel Jimenez, Associate Program Director at the Harvard Radiation Oncology Residency Program in Boston.

The NCCN Clinical Practice Guidelines in Oncology provide a wealth of information in the therapeutic management of early breast cancer. But how do those guidelines vary based on tumor biology? Here to give us a brief overview is Dr. Rachel Jimenez, Associate Program Director at the Harvard Radiation Oncology Residency Program in Boston.

Once we’ve confirmed a patient has EGFR-mutated lung cancer, how can we treat them? Joining Dr. Jacob Sands to discuss the current and future treatments for this mutation is Dr. Pasi Janne, a translational thoracic medical oncologist at the Dana-Farber Cancer Institute.

What is genomic testing, and how has this advancement become such an important part of lung cancer treatment? Dr. Jacob Sands is joined Dr. Ben Levy, an associate professor of oncology at the Johns Hopkins University School of Medicine to discuss targeted therapies and testing strategies in patients with lung cancer.

Oncology is a rapidly evolving field, so what do you we need to know about developments in cancer care around the world? Dr. Jacob Sands joins Dr. Lawrence Shulman, the Deputy Director of Clinical Services, Director of the Center of Global Cancer Medicine at the University of Pennsylvania, and a senior oncology advisor to Partners In Health, to give us a global perspective on cancer care.

How do challenges in our healthcare system and disparities in access to care impact cancer patients within our communities? Dr. Jacob Sands and Dr. Lawrence Shulman continue their important conversation on oncology around the world.

A 15-minute synopsis of the top hematology research in multiple myeloma presented at the 2020 ASH Annual Meeting. Learn about potential practice-changing data placed in a real-world context by a myeloma expert. This activity is an opportunity to stay up to date on the rapidly evolving myeloma landscape and to enhance your management and care strategies for patients with multiple myeloma.